Log in

IVERIC bio Stock Forecast, Price & News

+0.19 (+3.17 %)
(As of 11/24/2020 12:00 AM ET)
Today's Range
Now: $6.18
50-Day Range
MA: $6.09
52-Week Range
Now: $6.18
Volume492,791 shs
Average Volume783,089 shs
Market Capitalization$553.53 million
P/E RatioN/A
Dividend YieldN/A
IVERIC bio, Inc., a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan retinal diseases. The company is developing Zimura, an inhibitor of complement factor C5, which is in Phase IIb clinical trials for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration. It is also developing High temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases. The company has a license agreement with the University of Florida Research Foundation and the University of Pennsylvania for the development and commercialization of novel adeno-associated virus gene therapy product candidate for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa; and Best disease and other BEST1-related inherited retinal diseases. It also has a research agreement with the University of Massachusetts Medical School to develop gene therapy product candidates targeting Leber Congenital Amaurosis type 10 and autosomal recessive Stargardt disease; and IRDs associated with mutations in the USH2A gene. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. IVERIC bio, Inc. was founded in 2007 and is headquartered in New York, New York.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.59 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ISEE



Sales & Book Value

Annual Sales$209.98 million
Book Value$2.40 per share


Net Income$-58,860,000.00


Market Cap$553.53 million
Next Earnings Date2/25/2021 (Estimated)
+0.19 (+3.17 %)
(As of 11/24/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ISEE News and Ratings via Email

Sign-up to receive the latest news and ratings for ISEE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

IVERIC bio (NASDAQ:ISEE) Frequently Asked Questions

How has IVERIC bio's stock been impacted by COVID-19 (Coronavirus)?

IVERIC bio's stock was trading at $4.46 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ISEE shares have increased by 38.6% and is now trading at $6.18.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of IVERIC bio?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IVERIC bio in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for IVERIC bio

What stocks does MarketBeat like better than IVERIC bio?

Wall Street analysts have given IVERIC bio a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but IVERIC bio wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is IVERIC bio's next earnings date?

IVERIC bio is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for IVERIC bio

How were IVERIC bio's earnings last quarter?

IVERIC bio, Inc. (NASDAQ:ISEE) announced its quarterly earnings data on Saturday, November, 7th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.21) by $0.06.
View IVERIC bio's earnings history

What price target have analysts set for ISEE?

3 equities research analysts have issued 12 month target prices for IVERIC bio's stock. Their forecasts range from $13.00 to $13.00. On average, they anticipate IVERIC bio's share price to reach $13.00 in the next year. This suggests a possible upside of 110.4% from the stock's current price.
View analysts' price targets for IVERIC bio

Who are some of IVERIC bio's key competitors?

What other stocks do shareholders of IVERIC bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IVERIC bio investors own include Pfizer (PFE), Inovio Pharmaceuticals (INO), Novavax (NVAX), Maxar Technologies (MAXR), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Alibaba Group (BABA), Cisco Systems (CSCO) and Kinross Gold (KGC).

Who are IVERIC bio's key executives?

IVERIC bio's management team includes the following people:
  • Dr. David R. Guyer M.D., Exec. Chairman (Age 60, Pay $834.88k)
  • Mr. Glenn P. Sblendorio M.B.A., CEO, Pres & Director (Age 64, Pay $1.16M)
  • Mr. David F. Carroll, Sr. VP, CFO & Treasurer (Age 54, Pay $577.62k)
  • Mr. Keith Westby M.B.A., Sr. VP & COO (Age 45, Pay $577.11k)
  • Dr. Samir C. Patel, Co-Founder and Consultant (Age 59)
  • Dr. Abraham Scaria Ph.D., Chief Scientific Officer
  • Ms. Kathy Galante, VP of Investor Relations & Corp. Communications
  • Mr. Todd D.C. Anderman, VP, Gen. Counsel & Corp. Sec.
  • Ms. Amy R. Sheehan, Sr. VP & Chief HR Officer
  • Ms. Evelyn Harrison, Sr. VP & Chief Clinical Operations Officer

What is IVERIC bio's stock symbol?

IVERIC bio trades on the NASDAQ under the ticker symbol "ISEE."

Who are IVERIC bio's major shareholders?

IVERIC bio's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.51%), Consonance Capital Management LP (4.29%), Stonepine Capital Management LLC (2.64%), State Street Corp (1.30%), Acadian Asset Management LLC (0.57%) and HarbourVest Partners LLC (0.49%). Company insiders that own IVERIC bio stock include David Francis Carroll, David R Guyer, Glenn Sblendorio and Keith Westby.
View institutional ownership trends for IVERIC bio

Which major investors are selling IVERIC bio stock?

ISEE stock was sold by a variety of institutional investors in the last quarter, including Consonance Capital Management LP, Morgan Stanley, Acadian Asset Management LLC, Stonepine Capital Management LLC, JPMorgan Chase & Co., O Shaughnessy Asset Management LLC, and TD Asset Management Inc.. Company insiders that have sold IVERIC bio company stock in the last year include David R Guyer, and Keith Westby.
View insider buying and selling activity for IVERIC bio

Which major investors are buying IVERIC bio stock?

ISEE stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, First Trust Advisors LP, HarbourVest Partners LLC, AQR Capital Management LLC, Charles Schwab Investment Management Inc., Wells Fargo & Company MN, and California Public Employees Retirement System.
View insider buying and selling activity for IVERIC bio

How do I buy shares of IVERIC bio?

Shares of ISEE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is IVERIC bio's stock price today?

One share of ISEE stock can currently be purchased for approximately $6.18.

How big of a company is IVERIC bio?

IVERIC bio has a market capitalization of $553.53 million and generates $209.98 million in revenue each year. The company earns $-58,860,000.00 in net income (profit) each year or ($1.39) on an earnings per share basis. IVERIC bio employs 55 workers across the globe.

What is IVERIC bio's official website?

The official website for IVERIC bio is ivericbio.com.

How can I contact IVERIC bio?

IVERIC bio's mailing address is ONE PENN PLAZA 35TH FLOOR, NEW YORK NY, 10119. The company can be reached via phone at 212-845-8200 or via email at [email protected]

This page was last updated on 11/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.